Intact Vagal Innervation for and Glucagon-like Peptide-1 (GLP-1) Effects

University Hospital, Gentofte, Copenhagen

Status: Unknown

Conditions: Vagotomy, Truncal

Treatments: Drug: Dipeptidyl peptidase 4 (DPP 4) inhibitor; Other: oral glucose

Study type: Interventional

Funder types: Other

Identifiers

NCT01176760

Truncated isoglycemia

Details and patient eligibility

About

The aim of this study is to investigate the role of transmission via the vagal nerve for the effect of glucose and Glucagon-like peptide-1 (GLP-1) in respect to insulin secretion.

The hypothesis is that a great deal of the effects of GLP-1 is mediated via the nervous system and for this reason the investigators will research individuals with and without intact nervous supply.

Full description

GLP-1 is a potent enterogastron and incretin hormone. It is rapidly inactivated by dipeptidyl peptidase IV so only 10-15% enters the systemic circulation. This has led to the hypothesis that GLP-1 interact locally with afferent sensory nerve fibers. We investigated the role of intact vagal innervations on the effect of glucose and GLP-1 on the insulin secretion

Enrollment: 30 estimated patients

Sex: All

Ages: 18 to 90 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• normal fasting plasma glucose
• normal hemoglobin
• informed consent

Exclusion criteria

• type 1 diabetes mellitus or type 2 diabetes mellitus
• body mass index > 30
• inflammatory bowel disease
• intestinal surgery
• serum creatinine > 250 µM and/or albuminuria
• ALAT > 2 x normal value
• Severe cardiac insufficiency
• in treatment with medicine which cannot be paused for 12 hours

Trial design

Primary purpose: Basic Science

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

30 participants in 3 patient groups

Vago

Experimental group

Description:

Truncally vagotomized subjects (due to duodenal ulcer operation)

Treatment:

Other: oral glucose

Drug: Dipeptidyl peptidase 4 (DPP 4) inhibitor

Cardia

Experimental group

Description:

Truncally vagotomized subjects (due to cardia resection)

Treatment:

Other: oral glucose

Drug: Dipeptidyl peptidase 4 (DPP 4) inhibitor

Ctrl

Experimental group

Description:

Healthy matched control subjects

Treatment:

Other: oral glucose

Drug: Dipeptidyl peptidase 4 (DPP 4) inhibitor